Cornerstone Research worked with two experts who testified on Rule 14e-3 allegations that a hedge fund violated federal securities law on disclosures in cash tender offers. Retained by Latham & Watkins and by Wachtell, Lipton, Rosen & Katz When Valeant and Pershing Square Capital Management, a hedge fund, made a public announcement of an intended acquisition of Allergan in April 2014, a protracted takeover battle ensued. Pershing Square had acquired a 9.7 percent block of Allergan shares in stock and option transactions prior to the formal announcement of the tender offer for Allergan by Valeant. Allergan filed a lawsuit against Valeant and Pershing Square alleging that both firms violated Rule 14e-3 of the Securities Exchange Act of 1934 when Pershing Square acquired shares of Allergan wh

Join for free to read